AstraZeneca PLC (NASDAQ:AZN) shares bought by Drive Wealth Management LLC

Drive Wealth Management LLC boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 10.4% in the second quarter, according to the company in its most recent SEC disclosure. The firm owned 4,232 shares of the company’s stock after acquiring an additional 400 shares during the quarter. Drive Wealth Management LLC’s holdings in AstraZeneca were worth $330,000 as of its most recent SEC filing.

Several other institutional investors have recently made changes to their positions in AZN. Massachusetts Wealth Management purchased a new stake in shares of AstraZeneca during the second quarter valued at approximately $226,000. Retireful LLC acquired a new position in AstraZeneca in the second quarter worth $2,019,000. Ritholtz Wealth Management boosted its position in AstraZeneca by 12.7% in the second quarter. Ritholtz Wealth Management now owns 66,235 shares of the company’s stock worth $5,166,000 after buying an additional 7,478 shares during the last quarter. Waldron Private Wealth LLC purchased a new stake in AstraZeneca in the second quarter valued at $275,000. Finally, Summit Financial LLC purchased a new position in shares of AstraZeneca in the second quarter valued at $438,000. 20.35% of the shares are currently held by hedge funds and other institutional investors.

AstraZeneca trading up 0.4%

Shares of AstraZeneca opened at $87.62 on Monday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company’s fifty day moving average is $80.81 and its two hundred day moving average is $75.00. The company has a quick ratio of 0.69, a current ratio of 0.89, and a debt-to-equity ratio of 0.69. The firm has a market cap of $271.67 billion, a PE ratio of 42.95, a P/E/G ratio of 1.65 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN – Get Your Free Report ) last released its earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.01. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The firm had revenue of $12.45 billion for the quarter, compared to the consensus estimate of $12.62 billion. In the same period last year, the company posted earnings of $1.08 per share. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. analysts anticipate that AstraZeneca PLC will post 4.06 earnings per share for the current year.

AstraZeneca cuts dividend

The company also recently declared a semi-annual dividend, which will be paid on Monday, September 9th. Stockholders of record on Friday, August 9th will be given a $0.49 dividend. The ex-dividend date of this dividend is Friday, August 9. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio (DPR) is currently 48.04%.

Analysts on Wall Street are forecasting an increase

AZN has been the subject of several recent research reports. TD Cowen boosted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Citigroup upgraded shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Goldman Sachs Group began coverage on AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price objective for the company. Barclays raised AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Finally, Argus upped their target price on AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. AstraZeneca presently has an average rating of “Buy” and a consensus price target of $89.75, based on data from MarketBeat.com.

Get our latest analysis on AZN

About AstraZeneca

(Free report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbilocort, Teztri Saspireph, , Pulmicort, Bevespi and Daliresp for cardiovascular, renal, metabolism and oncology.

Featured stories

Get news and reviews for AstraZeneca Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca and related companies with MarketBeat.com’s FREE daily email newsletter.